The chief medical officer at Stoke Therapeutics discussed recent developments for zorevunersen, including the significance of breakthrough therapy designation and its plan for a phase 3 trial. [WATCH TIME: 5 minutes]
Barry Ticho, MD, PhD
Advertisement
Articles by Barry Ticho, MD, PhD
The chief medical officer at Stoke Therapeutics provided commentary on the promising mechanism of action of STK-001, an antisense agent, in the treatment of Dravet syndrome. [WATCH TIME: 3 minutes]
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Newly Unveiled EPIC Trial Pins Myasthenia Gravis Medications Nipocalimab Against Efgartigimod for Efficacy
2
Episode 153: Overviewing the 2025 Alzheimer's Association's Blood-Based Biomarker Guidelines
3
Revisiting the Salem Witch Trials Through a Modern Neurological Lens
4
Efgartigimod Treatment for CIDP Leads to Increased Spending, Study Shows
5
